Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veracyte Inc
(NQ:
VCYT
)
25.56
+2.97 (+13.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
November 20, 2023
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.
Via
Talk Markets
Topics
ETFs
Veracyte: Q3 Earnings Insights
November 07, 2023
Via
Benzinga
Veracyte Announces Third Quarter 2023 Financial Results
November 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
November 07, 2023
From
Veracyte, Inc.
Via
Business Wire
The Latest Analyst Ratings for Veracyte
October 20, 2023
Via
Benzinga
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
Veracyte to Participate in the Stephens Annual Investment Conference
November 02, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
October 27, 2023
From
Veracyte, Inc.
Via
Business Wire
7 Undervalued Stocks That Analysts Love Right Now
October 26, 2023
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal.
Via
InvestorPlace
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
October 17, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
October 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Stock Is Volatile After-Hours - Here's Why
October 04, 2023
Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier...
Via
Benzinga
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
October 04, 2023
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
September 28, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
September 28, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
September 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
September 21, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
September 07, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
September 06, 2023
From
Veracyte, Inc.
Via
Business Wire
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
September 02, 2023
The genetic test maker is rapidly increasing test volumes.
Via
The Motley Fool
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 29, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
August 22, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
August 15, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Second Quarter 2023 Financial Results
August 08, 2023
From
Veracyte, Inc.
Via
Business Wire
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
August 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
July 19, 2023
From
Veracyte, Inc.
Via
Business Wire
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
July 08, 2023
AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider.
Via
InvestorPlace
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
June 20, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
June 12, 2023
From
Veracyte, Inc.
Via
Business Wire
Market Mixes It Up With A Broad Rally
June 05, 2023
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive.
Via
Talk Markets
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.